VIV.V · Avivagen Inc

-

Please sign in to comment on VIV.V

1 Comment

Admin

4 years, 1 month ago

Avivagen Inc is currently in a long term downtrend where the price is trading 20.2% below its 200 day moving average.

From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.9.

Avivagen Inc's total revenue rose by 5.7% to $262K since the same quarter in the previous year.

Its net income has increased by 4.9% to $-1M since the same quarter in the previous year.

Finally, its free cash flow grew by 64.2% to $-355K since the same quarter in the previous year.

Based on the above factors, Avivagen Inc gets an overall score of 4/5.

Sector	Healthcare
ISIN	CA05382F2026
Industry	Drug Manufacturers - Specialty & Generic
Exchange	V
CurrencyCode	CAD

Market Cap	388K
PE Ratio	None
Target Price	1.38
Beta	1.0
Dividend Yield	None

ABOUT

Avivagen Inc

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

VIV.V · Avivagen Inc

-

Avivagen Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Avivagen Inc using a moving average strategy